Search
Displaying 441–450 of 645 for “retinal diseases”
-
Nouvelle Lumière: French Bionic Retina in a Human Study
Research NewsThe French retinal implant developer Pixium quietly launched a clinical trial for its Intelligent Retinal Implant System 1 (IRIS1) in France, Austria and Germany.
-
Gene Therapy Revives Cones Long After They Stop Working
Research NewsA Foundation-funded research group is developing a gene therapy that revives degenerating cones, enabling them to regain their ability to respond to light and provide vision.
-
ARVO 2024 Highlight: New Gene Linked to RP in People with African Ancestry
Research NewsThe discovery will help geneticists diagnose more RP patients with African descent.
-
Disease
Geographic atrophy (GA) is an advanced form of dry age-related macular degeneration (AMD) that leads to progressive vision loss.
-
Geographic Atrophy: The Advanced Form of Dry AMD
Research NewsGeographic atrophy causes significant central vision loss and remains an unmet medical need.
-
Promising Results from Lab Study of Gene Therapy for Cone-Rod Dystrophy
Research NewsThe study is an important step toward a clinical trial of the approach
-
Research News
A Phase 3 trial for the treatment is planned
-
Clinical Research Fellowship Award (CRFA)
Objective/Goal: The program will provide funding for post-residency clinical fellowships in inherited orphan retinal degenerations. The goal is to increase the number of clinician-scientists with expertise and commitment to provided clinical care to patients with inherited orphan retinal degenerations. This program supports up to three post-residency clinicians for one (1) year. $65,000/year
-
Encouraging Vision Improvements Reported in ReNeuron's Cell-Therapy Clinical Trial
Research NewsReNeuron, a cellular therapy developer in the UK, has reported vision improvements in the treated eyes of the first three retinitis pigmentosa (RP) patients in the Phase II part of the Phase I/II clinical trial for its proprietary human retinal progenitor cells (hRPC). The Phase I portion of the trial, completed last year, primarily assessed safety in subjects with minimal remaining vision.
-
AGTC Launches XLRP Gene Therapy Clinical Trial at Five Sites in U.S.
Research NewsTaking place at five locations in the United States, the clinical trial will enroll approximately 15 males with X-linked retinitis pigmentosa caused by mutations in the gene RPGR and will primarily evaluate safety.
